Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.54 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.54 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22139844 | 0.90 | ADORA1 (0.61) | SLC29A1ADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL26360925 | 0.90 | ADORA1 (0.61) | SLC29A1ADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL18512901 | 0.83 | MEN1 (0.66) | SLC29A1ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL22393065 | 0.83 | ADORA3 (0.61) | SLC29A1ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL22402607 | 0.83 | ADORA3 (0.61) | SLC29A1ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL26298122 | 0.82 | ADORA1 (0.57) | SLC29A1ADORA1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2221275 | 0.81 | ADORA2A (0.61) | SLC29A1ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2221268 | 0.81 | ADORA2A (0.61) | SLC29A1ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL2220833 | 0.80 | ADORA1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BMEN1 | |
| SCHEMBL2220825 | 0.80 | ADORA1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | SLC29A1 356/4885ADORA1 336/4885PRKAG1 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.